These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 27923273)

  • 1. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To chelate or not to chelate in MDS: That is the question!
    Zeidan AM; Griffiths EA
    Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
    Shammo JM; Komrokji RS
    Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
    Gattermann N
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA
    Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Leitch HA; Vickars LM
    Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C; Clissa C; Stanzani M
    Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N
    Int J Hematol; 2008 Jul; 88(1):24-29. PubMed ID: 18581200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
    Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
    Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron overload in myelodysplastic syndromes (MDS).
    Gattermann N
    Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
    Merkel DG; Nagler A
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):817-29. PubMed ID: 24641787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron chelation therapy in MDS: does it improve survival?
    Leitch HA
    Leuk Res; 2010 Jul; 34(7):852-3. PubMed ID: 20346508
    [No Abstract]   [Full Text] [Related]  

  • 15. Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
    Greenberg PL
    J Natl Compr Canc Netw; 2006 Jan; 4(1):91-6. PubMed ID: 16403408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
    Kattamis A; Aydinok Y; Taher A
    Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron overload in MDS-pathophysiology, diagnosis, and complications.
    Gattermann N; Rachmilewitz EA
    Ann Hematol; 2011 Jan; 90(1):1-10. PubMed ID: 20938663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
    Zeidan AM; Pullarkat VA; Komrokji RS
    Crit Rev Oncol Hematol; 2017 Sep; 117():57-66. PubMed ID: 28807236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron overload in myelodysplastic syndromes.
    Mahesh S; Ginzburg Y; Verma A
    Leuk Lymphoma; 2008 Mar; 49(3):427-38. PubMed ID: 18297518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.